You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.
The company said it completed 82,000 Cologuard tests during the quarter, a 114 percent growth in test volume during the three-month period.
For full year 2016, the company reported 8 percent revenue growth and net income of $2.02 billion.
The firm also reported that 2016 preliminary revenues were up 14 percent, and that Nanosphere MDx platform revenues rose 32 percent.
The company lowered its financial guidance for fiscal 2016, citing delays in recognizing fourth quarter revenue from its pharma services business.
The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The company attributed the increase to gains in its molecular business, including $7.4 million in revenues from Nanosphere, which Luminex acquired in June.
The company attributed the uptick in revenues to a 100 percent increase in the number of Cologuard colon cancer tests it completed during the quarter.
The company's revenues were in line with analyst expectations, while its adjusted earnings per share of $.87 beat expectations.
After reporting FY2016 revenues below market expectations, Myriad discussed plans to increase sales of Prolaris, Vectra DA, EndoPredict, GeneSight, and myChoice HRD.